Clinic infusions for bulging, painful, or double-vision thyroid eye disease are not the same as everyday dry-eye drops. Tepezza (teprotumumab-trbw) is a prescription monoclonal antibody that blocks the insulin-like growth factor-1 receptor (IGF-1R), the receptor that the natural IGF-1 peptide hormone uses. The labeled use is thyroid eye disease in adults, and the everyday takeaway is to plan hearing checks, glucose monitoring, and infusion-reaction watch points with the eye and endocrine teams before the series starts.
What thyroid eye disease is and what Tepezza targets
National Eye Institute guidance on Graves eye disease describes swelling behind the eyes that can push the globes forward, dry or gritty eyes, lid retraction, double vision, and light sensitivity. Smoking raises risk among people with Graves disease. Tepezza is not a substitute for thyroid hormone management, artificial tears, or surgical plans when those apply. MedlinePlus places teprotumumab in the monoclonal-antibody class that interferes with a protein pathway driving orbital inflammation, which is why the IGF-1 peptide receptor link matters for counseling even though the drug itself is an antibody, not a short peptide vial.
Hearing, glucose, gut, and infusion watch points
The DailyMed label warns that Tepezza may cause severe hearing impairment, including hearing loss that can be permanent, and it directs clinicians to assess hearing before, during, and after treatment. MedlinePlus also tells patients to report hearing problems and notes that hearing is monitored around the infusion course. The label further warns about hyperglycemia, including the need for glucose control in people with diabetes or prediabetes; infusion reactions that may require slowing or interrupting the drip; inflammatory bowel disease flares even without a prior IBD history; and encephalopathy symptoms that warrant urgent clinical review. Embryo-fetal toxicity counseling and effective contraception through treatment and for months after the last infusion are also on the label for people who can become pregnant.
None of those warnings turn Tepezza into a home peptide kit. Infusions happen in a medical setting over about an hour to an hour and a half on a multi-week clinic schedule the specialty team sets. Bring an updated medicine list, ask who will check hearing and glucose, and say immediately if you feel hot, short of breath, or develop a rapid heartbeat during or soon after an infusion.
Questions worth asking before the first infusion
Ask how thyroid eye disease severity was measured, whether smoking-cessation support is part of the plan, how hearing and blood sugar will be tracked, what IBD or neurologic symptoms should trigger a same-day call, and how pregnancy prevention is handled if it applies. Tepezza is one specialized option inside a broader thyroid-eye-disease plan, not a cosmetic “eye peptide” and not the same pathway as thyroid-cancer lab adjuncts that use recombinant TSH.
Not medical advice.
Sources
- DailyMed: Tepezza (teprotumumab-trbw) prescribing information
- MedlinePlus: Teprotumumab-trbw injection
- National Eye Institute: Graves eye disease
- UniProt: IGF-1 (P05019)
Related reading
- Thyrogen thyroid cancer labs without hormone withdrawal
- IGF-1 blood test results explained
- Semaglutide NAION sudden vision loss
By The Everyday Brief. AI-assisted drafting with human editorial review. Not medical advice. Not veterinary advice.